New Report Exposes Delays in UK Cannabinoid Research: Home Office Inaction Hindering Clinical Trials
Read the press release for the launch of our report – Strengthening Cannabinoid Research & Development.
Menu
Professor Trevor Jones CBE FMed Sci
Zack Bellman
Positioned at the heart of the life sciences sector, the Cannabinoid Research & Development Group UK is a new research strategy group led by academics, researchers, clinicians, patients and industry.
The group will propel scientific research and development of pharmaceutical cannabinoid-related products in the UK.
Our ambition is to develop and implement a comprehensive strategy to transform the UK into the global leader in cannabinoid research and medicine development.
We will build a robust ecosystem by integrating universities, research institutions, investors, businesses, and the NHS – driving innovation and development, nurturing top talent and fostering advances in healthcare.
Read the press release for the launch of our report – Strengthening Cannabinoid Research & Development.
Read CRDG Co-chair Professor Trevor Jones’ letter to key government ministers in the Home Office and the Department for Science, Innovation and Technology, acknowledging the ongoing support for the UK Life Sciences sector and urging them to implement the ACMD’s recommendations from December 2023.
Artelo is currently developing three different cannabinoid-based drugs. Learn about their history and plans for the future.
The CRDG represents an evolution of The Centre for MC, which formed in November 2019. Our archive includes all reports and papers published by the CDRG and the CMC.
Artelo is currently developing three different cannabinoid-based drugs. Learn about their history and plans for the future.
Sign up for CRDG news and updates.